Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone + bupivacaine + adrenaline + hyaluronidase + saline
- Development stage
- Unknown
- Lead developer
- Postgraduate Institute of Dental Sciences
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Submucosal Infiltration
01
Overview
This combination drug is a multi-component tumescent solution developed for use in oral and maxillofacial surgery, specifically for the surgical removal of impacted mandibular third molars. The formulation consists of dexamethasone (a synthetic glucocorticoid), bupivacaine (a long-acting local anesthetic), adrenaline (a vasoconstrictor), and hyaluronidase (an enzyme that increases tissue permeability), all diluted in normal saline. The solution is administered via submucosal infiltration to provide prolonged analgesia, reduce postoperative edema (swelling), and minimize trismus (limited jaw opening) by modulating the inflammatory response and extending the duration of local anesthesia. The intervention was evaluated in a split-mouth randomized controlled trial by the Postgraduate Institute of Dental Sciences Rohtak to assess its efficacy in reducing postoperative inflammatory sequelae.
- Other names
- Tumescent steroid infiltrationTumescent solution
02
Targets
ADRA1A (α1A)ADRB2 (β2)GR (Glucocorticoid receptor)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)
Beyond the preview
Go deeper on dexamethasone + bupivacaine + adrenaline + hyaluronidase + saline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone + bupivacaine + adrenaline + hyaluronidase + saline.